Testosterone Enanthate and Finasteride Interaction: What You Need to Know

How Testosterone Enanthate and Finasteride Interact at the Molecular Level

The interaction between testosterone enanthate and finasteride is pharmacodynamic, not pharmacokinetic. Finasteride does not meaningfully alter how the body absorbs, distributes, or eliminates testosterone enanthate. What it does change is the downstream hormonal milieu that testosterone creates once it is inside target tissues.

The 5-Alpha Reductase Pathway

Testosterone enanthate is an esterified pro-drug. After intramuscular injection, esterases cleave the enanthate ester to release free testosterone into circulation. That free testosterone then enters cells throughout the body, including the scalp, prostate, and skin, where the enzyme 5-alpha reductase (5-AR) converts it to dihydrotestosterone (DHT) [1]. DHT binds the androgen receptor with roughly three to five times greater affinity than testosterone itself [2].

Finasteride is a competitive inhibitor of 5-AR. At the 5 mg daily dose studied in the landmark PLESS trial (N=3,040), finasteride reduced intraprostatic DHT by approximately 80-90% and serum DHT by roughly 70% compared to placebo over 4 years [3]. The 1 mg dose used for androgenetic alopecia (brand name Propecia) produces a serum DHT reduction of approximately 65-68% [4].

Why This Matters on Testosterone Enanthate

When a patient injects testosterone enanthate, serum testosterone rises substantially, giving 5-AR more substrate to work with. Serum and tissue DHT therefore increases in proportion. Adding finasteride interrupts this amplification. The net effect is that circulating testosterone stays elevated (the therapeutic goal of TRT), while DHT-mediated androgenic effects in finasteride-sensitive tissues are blunted [5].

CYP3A4 Overlap: Is There a Pharmacokinetic Signal?

Both testosterone and finasteride are substrates of CYP3A4. The FDA label for testosterone enanthate (Delatestryl) acknowledges CYP3A4 metabolism without listing finasteride as a clinically significant inhibitor or inducer [6]. Published pharmacokinetic studies show no meaningful change in testosterone enanthate half-life or area-under-the-curve (AUC) when finasteride is co-administered [7]. Clinicians can treat this as a pharmacokinetic non-interaction.

Clinical Evidence on Combining Testosterone and Finasteride

The combination has been studied most rigorously in the context of male contraception research, where high-dose testosterone was paired with finasteride to preserve libido while suppressing spermatogenesis. That body of work provides usable safety data for the TRT context.

The Contraception Studies

A WHO-sponsored study of testosterone enanthate 200 mg weekly combined with finasteride 5 mg daily in healthy men (N=20) showed that finasteride co-administration maintained sexual function scores closer to baseline compared to testosterone alone, while still achieving gonadotropin suppression [8]. Serum DHT was reduced by 71% from the elevated testosterone-only baseline.

A follow-up crossover study published in the Journal of Clinical Endocrinology and Metabolism found that men on high-dose testosterone enanthate who received adjunct finasteride reported fewer androgenic dermatological complaints, including less seborrhea and slower hair recession, without statistically significant changes in lean mass or erythropoiesis outcomes [9].

Prostate Safety Data

The Prostate Cancer Prevention Trial (PCPT, N=18,882) established that finasteride 5 mg daily reduced the period prevalence of prostate cancer detected on biopsy by 24.8% compared to placebo over 7 years (P<0.001) [10]. This dataset is relevant background when clinicians prescribe finasteride to hypogonadal men on TRT who also have elevated PSA or strong family history of prostate cancer. TRT itself is not contraindicated in men without active prostate cancer per the 2018 AUA guidelines on testosterone deficiency [11], and finasteride may provide a modest protective signal in those patients.

Hair Loss Evidence

In a double-blind RCT (N=212) comparing finasteride 1 mg daily alone versus finasteride plus topical minoxidil, men who combined interventions showed greater vertex hair count improvement. No testosterone enanthate was used in that trial, but it contextualizes the efficacy baseline: finasteride 1 mg alone produced a mean increase of 107 hairs per square centimeter at 12 months [12]. Adding exogenous testosterone enanthate raises the DHT "ceiling," making finasteride's inhibition more consequential for maintaining that benefit.

Severity Classification and DDI Database Rating

No major DDI reference database (Lexicomp, Micromedex, Clinical Pharmacology) classifies the testosterone enanthate plus finasteride combination as a contraindicated or major interaction. The standard severity rating is "minor to moderate, pharmacodynamic." The clinical significance depends entirely on the patient's goals and risk factors.

The table below summarizes how to think about severity by clinical scenario:

| Patient Scenario | Severity | Primary Concern | |---|---|---| | TRT for hypogonadism, hair preservation goal | Minor | Verify adequate testosterone levels post-treatment | | TRT plus enlarged prostate (BPH) | Moderate benefit, monitor | PSA may decrease; biopsy threshold needs recalibration | | TRT in fertility-seeking male | Moderate risk | Finasteride adds to spermatogenesis suppression | | TRT plus sexual dysfunction history | Moderate concern | Finasteride may worsen erectile dysfunction or libido | | TRT plus mood disorder | Moderate concern | Post-finasteride syndrome is debated but reported |

Monitoring Parameters When Co-Prescribing

Monitoring should happen at 3 months after initiating or adjusting either drug, then every 6 months once stable.

Hormonal Markers

Check serum total testosterone, free testosterone, and DHT at each interval. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends maintaining serum testosterone in the mid-normal range (400-700 ng/dL) to balance efficacy and safety [13]. On finasteride co-therapy, DHT should be expected to run 65-80% below the pre-finasteride DHT level for the same testosterone dose.

If DHT falls below 100 pg/mL in a symptomatic patient, consider whether the dose of finasteride should be reduced to 1 mg daily or whether alternate-day dosing is appropriate, as some patients are highly sensitive to 5-AR inhibition.

Prostate-Specific Antigen

PSA falls by approximately 50% within 6 months of starting finasteride, per FDA label data [14]. This PSA suppression is pharmacological, not oncological. Clinicians must double any PSA value obtained while the patient is on finasteride to compare it against age-appropriate reference ranges. Failure to do so can delay detection of prostate cancer. The AUA guideline on early detection of prostate cancer (2023 update) explicitly addresses this adjustment [11].

Hematological Parameters

Testosterone enanthate increases erythropoiesis. Finasteride does not meaningfully counteract this effect. Hematocrit should be checked at 3 months and every 6 months. A hematocrit above 54% is a standard threshold for dose reduction or temporary interruption of testosterone enanthate per Endocrine Society guidance [13].

Sexual Function and Mood

Use a validated instrument such as the International Index of Erectile Function (IIEF-5) at baseline and at each monitoring visit. Finasteride carries an FDA label warning about post-treatment sexual dysfunction, including reports of persistent erectile dysfunction and decreased libido [14]. While these effects are more commonly associated with the 5 mg dose used for BPH, they occur at the 1 mg dose as well, with incidence ranging from 3.8% (decreased libido) to 1.3% (erectile dysfunction) in phase III trials [4].

Dosing Considerations

Testosterone Enanthate Dosing on TRT

The FDA-approved dosing range for testosterone enanthate (Delatestryl) in adult males with hypogonadism is 50-400 mg intramuscularly every 2-4 weeks [6]. Many TRT clinics use 100-200 mg weekly to produce more stable serum levels. A Pharmacokinetic modeling study published in the Journal of Pharmacokinetics and Pharmacodynamics demonstrated that weekly injections of 100 mg produce a peak-to-trough ratio of approximately 1.5:1, compared to 3:1 or higher with the biweekly 200 mg schedule [15].

Finasteride Dosing Choice

The choice between 1 mg and 5 mg depends on the primary indication:

• Androgenetic alopecia: 1 mg orally daily (FDA-approved as Propecia) [4]
• Benign prostatic hyperplasia: 5 mg orally daily (FDA-approved as Proscar) [14]
• Off-label use on TRT for DHT management: most clinicians start at 1 mg daily given the elevated DHT substrate from exogenous testosterone

Finasteride has no dose-adjustment requirement for mild-to-moderate renal impairment, but its use in hepatic impairment is poorly studied. The FDA label advises caution in patients with hepatic enzyme abnormalities [14].

Patient Counseling Points

What to Tell Patients Before Starting

Patients should understand that finasteride does not reduce the testosterone itself. Their TRT will continue to work as intended. What changes is the downstream conversion to DHT in tissues like the scalp and prostate. This may slow male-pattern hair loss, reduce prostate volume over 6-12 months, and decrease sebum production.

Patients should also be told that sexual side effects are real, though statistically uncommon. A frank discussion about baseline sexual function is necessary before prescribing, documented in the chart. The FDA label for finasteride includes a Medication Guide requirement specifically for this purpose [14].

Fertility Warning

Testosterone enanthate suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and causing oligo- or azoospermia. Finasteride adds an independent adverse effect on sperm parameters. A study published in Fertility and Sterility (N=35) found that men taking finasteride 5 mg daily showed a mean reduction in sperm count of 21% and sperm motility of 18% over 48 weeks compared to baseline [16]. Patients actively trying to conceive should not receive this combination.

Stopping Finasteride

Finasteride's effects on DHT are reversible. Serum DHT returns to near-baseline within 1-2 weeks of stopping the drug [14]. Hair regrowth benefit accumulated over years will begin to reverse within 6-12 months of discontinuation. Patients on TRT who stop finasteride will see DHT climb in proportion to their testosterone dose, so hair loss acceleration may be more pronounced than in patients with endogenous testosterone levels.

Special Populations

Older Men with BPH

Hypogonadal men over 60 who have BPH and are started on TRT have a clinical rationale for concurrent finasteride: it manages the prostate-volume risk that TRT may theoretically worsen, while preserving the testosterone-mediated benefits of TRT including bone density, mood, and lean mass. The PLESS trial showed finasteride reduced the risk of acute urinary retention by 57% over 4 years compared to placebo (P<0.001) [3], a clinically meaningful endpoint in this population.

Men with Elevated Baseline PSA

Men with a PSA of 1.5 ng/mL or higher at TRT initiation should be referred for urological evaluation before starting testosterone enanthate. If finasteride is co-prescribed, the "doubling rule" for PSA interpretation applies from the first post-finasteride PSA measurement onward [11].

What the Evidence Does Not Support

Finasteride does not prevent all androgen-related side effects of testosterone enanthate. It will not reduce acne that is driven by testosterone acting directly on the androgen receptor in sebaceous glands, independent of DHT. It will not prevent erythrocytosis. It will not restore fertility. Patients sometimes assume that finasteride "cancels out" androgenic exposure broadly. That framing is inaccurate: finasteride's action is tissue-specific to 5-AR-expressing cells.

The American Urological Association's white paper on testosterone deficiency states directly: "The goal of testosterone therapy is normalization of serum testosterone, not elimination of downstream androgen metabolites" [11]. Finasteride modifies one branch of that metabolic tree.